Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease
NCT06081062
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Fabry Disease
Interventions
BIOLOGICAL:
Fabagal® (Agalsidase beta)
DRUG:
Active comparator (Agalsidase beta)
Sponsor
ISU Abxis Co., Ltd.